Clinical trials: Risperidone
Attention Deficit Disorder With Hyperactivity
Treatment of Severe Childhood Aggression (The TOSCA Study)
This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00796302
- Testing
- Methylphenidate HCl, Risperidone, Parent Management Training (PMT)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- Michael Aman
Schizophrenia
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events.
- Trial name
- SHINE (NCT03893825)
- Testing
- TV-46000
- Where
- 90 sites in United States, Bulgaria and 3 more
- Volunteers
- 336 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Bipolar Disorder
Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar
The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.
- Trial name
- NCT00176202
- Testing
- Divalproex Sodium, risperidone
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of Illinois Chicago
Sleep Disorders, Circadian Rhythm, Insomnia
Actigraphic Analysis of Treatment Response
The study examines and illustrates the utility of utilizing actigraphic measurements to assess treatment response.
- Conditions
- Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
- Trial name
- NCT00723580
- Testing
- risperidone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Child Psychopharmacology Institute
Bipolar Disorder
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder
The purpose of this study is to learn more about weight gain and related side effects when children are treated with antipsychotic medicine for mood disorders.
- Trial name
- PAMS (NCT00746252)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Bipolar Disorder
Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders
The primary aim of this proposal is to conduct a preliminary controlled trial of valproate and risperidone in children ages 3-7 yr. with bipolar disorders.
- Trial name
- NCT00221403
- Testing
- Risperidone oral solution, Valproate Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Bipolar Disorder
Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents
This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
- Trial name
- TEAM (NCT00057681)
- Testing
- Lithium carbonate, Valproate, Risperidone
- Where
- 5 sites in United States
- Volunteers
- 379 people
- Sponsor
- Washington University School of Medicine
Autistic Disorder
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will provide evidence-based guidance in the selection and monitoring of drug treatment of autism.
- Trial name
- BAART (NCT01333072)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical University of South Carolina
Schizophrenia, Schizoaffective Disorder
Optimizing Response in Psychosis Study
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
- Trial name
- ORP (NCT00314327)
- Testing
- long-acting injectable risperidone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwell Health
Schizophrenia
Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.
- Trial name
- TEOSS (NCT00053703)
- Testing
- Risperidone, Olanzapine (enrollment closed in this treatment), Molindone
- Where
- 4 sites in United States
- Volunteers
- 116 people
- Sponsor
- University of North Carolina, Chapel Hill
Aggression, Attention Deficit-Hyperactivity
Metabolic Effects of Antipsychotics in Children
The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat…
- Conditions
- Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders
- Trial name
- MEAC (NCT00205699)
- Testing
- risperidone, olanzapine, aripiprazole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia
Oculomotor and Spatial Cognition Deficits in Schizophrenia
DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia.
- Trial name
- NCT00931996
- Testing
- Antipsychotic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Autistic Disorder, Autism
A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical…
- Trial name
- NCT00576732
- Testing
- Risperidone high dose, Risperidone low dose
- Where
- 20 sites in United States
- Volunteers
- 96 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
High Risk MC4R Genotype, Low Risk MC4R Genotype
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
We will conduct a 12-week, randomized open label study, comparing usual care (UC) antipsychotic treatment (aripiprazole, quetiapine, risperidone) with ziprasidone (ZIP) in children and adolescents aged 13-18 years old.
- Conditions
- High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
- Trial name
- NCT01844700
- Testing
- Ziprasidone, aripiprazole, quetiapine, or risperidone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwell Health
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Risperidone-induced Hyperprolactinemia
Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia
The purpose of this study is to determine whether calcium and vitamin D supplementation, over a nine-month period, optimizes bone mineralization in boys with risperidone-induced hyperprolactinemia.
- Trial name
- NCT00799383
- Testing
- Calcium and Vitamin D
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Chadi A. Calarge
Autism
Pharmacogenomics in Autism Treatment
Autism is a complex neurodevelopmental disorder that is thought to involve an interaction between multiple and variable susceptibility genes, environmental factors, and epigenetic effects.
- Trial name
- PG (NCT00584701)
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of California, San Francisco